Novel cell therapies include cell preparations defined by various criteria and may be applicable to patients suffering from autoimmune, neurologic and hematologic disorders as well as heart diseases and so on. The therapeutic potential of, for example, cytotoxic T cells, tumor vaccines and mesenchymal stem cells (MSCs) is undergoing extensive clinical testing in areas such as cancer, tissue repair in connective tissue disorders and heart repair as well as immune modulation in the setting of stem cell transplantation. In other areas, including immunological disorders such as rheumatoid arthritis and vasculitides, MSC treatment is about to enter the clinical arena.
Although these therapies may be promising and prove to be of clinical use, clinical trials are often small with a limited follow-up. Detection of long-term beneficial effects, as well as late and rare side effects, would require a large number of patients followed over many years. Little is known of the in vivo risks of infused cell products manipulated or expanded ex vivo. A risk of ectopic tissue formation, malignant transformation of the cell product or secondary malignancies, as observed occasionally in certain experimental animal models, may or may not pose true clinical risks.
To collect data on patients treated with novel therapies, and allow for retrospective analyses of risks and benefits, a new registry has been opened in the European Group for Blood and Marrow Transplantation (EBMT) Registry database managed through ProMISe. The Cell Therapy Registry (CTR) aims to collect data on fetal or adult stem cells or hematopoietic progenitor cells used for treatment other than hematopoietic stem cell transplantation or donor lymphocyte infusion, as well as clinical characteristics and outcome of the patients. Data will be collected on the source and characteristics of the cell graft, in vivo or ex vivo cell manipulation and the cell origin (autologous versus allogeneic). Data will include details on patients treated with MSCs for instance, to enhance hematopoietic engraftment, for prophylaxis and treatment of GvHD. The registry will also include data on patients treated by other disciplines for neurologic, rheumatologic, cardiac and inflammatory bowel diseases and tissue regeneration. The registry will contain a MED A form, common for all types of cell therapies collecting basic data allowing for detailed retrospective data collection. The registry will eventually evolve to include MED B forms, specific for disease category (rheumatology, neurology, hematology, and so on) and, in some cases, specific for the cell graft, such as in MSC transplantation.
The EBMT has also formed a Developmental Committee focusing on emerging cell therapies besides hematopoietic stem cell transplantation. The committee members include, besides hematology, representatives from rheumatology, neurology, cardiology, immunology and other disciplines where novel cell therapies may be used clinically in the future.
In an attempt to facilitate international multicenter trials, a group of centers organized in the Developmental Committee has adopted a common MSC expansion protocol. The EBMT-MSC expansion consortium provides a standardized protocol for expansion of clinical grade MSCs, including standard operating procedures and guidelines for the phenotypic characterization of the cells and release criteria for the cell batch. Harmonized production and phenotypic characterization of the cells will allow collaborative trials using cells generated under similar conditions in several academic centers. Several such studies are underway, evaluating the efficacy of MSCs in prevention and treatment of GvHD and for promotion of engraftment and prevention of graft rejection in haploidentical and cord blood transplants.
The rapidly developing field of clinical cell therapies requires an integrated approach and collaboration at an international level. The field is rapidly expanding and includes cell preparations defined by various criteria and may be applicable to patients suffering from many disorders. To date, clinical experience regarding both the positive effects of such treatments and the risk of possible side effects, is very limited. The EBMT-CTR aims to collect data on patients treated with novel therapies for retrospective data analyses and as a basis for future collaborative efforts. 
